Core Cap Advisors, LLC Kal Vista Pharmaceuticals, Inc. Transaction History
Core Cap Advisors, LLC
- $2.64 Billion
- Q3 2025
A detailed history of Core Cap Advisors, LLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 23 shares of KALV stock, worth $251. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23Holding current value
$251% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KALV
# of Institutions
150Shares Held
54.9MCall Options Held
1.07MPut Options Held
90.1K-
Vr Adviser, LLC New York, NY6.73MShares$73.5 Million15.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.96MShares$54.2 Million1.93% of portfolio
-
Tang Capital Management LLC San Diego, CA4.94MShares$54 Million3.35% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.89MShares$53.4 Million2.92% of portfolio
-
Vestal Point Capital, LP New York, NY4.68MShares$51.1 Million2.78% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $269M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...